Oral cancer pills for neuroendocrine tumors: study on tolerance and quality of life
Part of Cancer clinical trials.
This study looks at how well patients with neuroendocrine tumors handle oral cancer pills and how those pills affect their quality of life. The goal is to improve support and education for people taking these medications at home.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with a neuroendocrine tumor (NET).
- Your doctor plans to treat you with a cancer pill (for example: everolimus, sunitinib, cabozantinib, temozolomide, lenvatinib, or others).
- You agree to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with advanced neuroendocrine tumors (NETs) that cannot be removed by surgery or have spread. Its goal is to see how long patients can live without having serious side effects from treatment, so doctors can better understand which treatments are worth the risks.
This study follows people after surgery to remove neuroendocrine tumors (NETs) from the stomach, intestines, or pancreas. It aims to understand long-term outcomes and quality of life.
This study looks at how internal radiation therapy (RIV) affects quality of life in people with neuroendocrine tumors. It aims to understand how well patients tolerate this treatment and how it impacts daily life.
This study follows patients who take oral anticancer drugs and take part in a special monitoring program at Lyon-Sud hospital. It aims to understand what affects treatment safety and outcomes.
This trial studies how cancer and its treatment affect your eating and food-related quality of life. By filling out a questionnaire, you can help doctors better understand and address these issues.
This study asks people with neuroendocrine tumors to report how they’re doing, including quality of life and quality of care. Your answers can help doctors and hospitals understand what support works best.
Hear when a new Neuroendocrine (NE) Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.